Canada Life’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $9.57M | Buy |
72,581
+558
| +0.8% | +$74K | 0.02% | 529 |
|
|
2025
Q4 | $10.2M | Sell |
72,023
-966
| -1% | -$140K | 0.02% | 516 |
|
|
2025
Q3 | $10.2M | Sell |
72,989
-2,147
| -3% | -$291K | 0.01% | 561 |
|
|
2025
Q2 | $9.45M | Sell |
75,136
-14,253
| -16% | -$1.63M | 0.02% | 566 |
|
|
2025
Q1 | $9.89M | Sell |
89,389
-4,393
| -5% | -$557K | 0.02% | 559 |
|
|
2024
Q4 | $12.8M | Sell |
93,782
-6,991
| -7% | -$865K | 0.02% | 509 |
|
|
2024
Q3 | $11.6M | Buy |
100,773
+9,092
| +10% | +$1.25M | 0.02% | 539 |
|
|
2024
Q2 | $12.6M | Buy |
91,681
+11,278
| +14% | +$1.55M | 0.02% | 508 |
|
|
2024
Q1 | $11.1M | Sell |
80,403
-4,914
| -6% | -$671K | 0.02% | 533 |
|
|
2023
Q4 | $11.2M | Sell |
85,317
-6,700
| -7% | -$771K | 0.02% | 510 |
|
|
2023
Q3 | $10.3M | Sell |
92,017
-5,593
| -6% | -$589K | 0.02% | 511 |
|
|
2023
Q2 | $9.23M | Sell |
97,610
-1,298
| -1% | -$127K | 0.02% | 538 |
|
|
2023
Q1 | $10M | Sell |
98,908
-889
| -0.9% | -$92.5K | 0.02% | 530 |
|
|
2022
Q4 | $11.9M | Buy |
99,797
+2,373
| +2% | +$278K | 0.03% | 483 |
|
|
2022
Q3 | $10.3M | Sell |
97,424
-7,667
| -7% | -$778K | 0.03% | 497 |
|
|
2022
Q2 | $10.3M | Buy |
105,091
+6,153
| +6% | +$568K | 0.03% | 525 |
|
|
2022
Q1 | $9.67M | Sell |
98,938
-6,182
| -6% | -$524K | 0.02% | 591 |
|
|
2021
Q4 | $8.94M | Buy |
105,120
+29,042
| +38% | +$2.67M | 0.02% | 621 |
|
|
2021
Q3 | $7.34M | Buy |
76,078
+8,023
| +12% | +$758K | 0.02% | 648 |
|
|
2021
Q2 | $6.62M | Sell |
68,055
-5,748
| -8% | -$551K | 0.02% | 684 |
|
|
2021
Q1 | $7.15M | Buy |
73,803
+38,285
| +108% | +$4.01M | 0.02% | 661 |
|
|
2020
Q4 | $3.4M | Sell |
35,518
-5,988
| -14% | -$578K | 0.01% | 887 |
|
|
2020
Q3 | $3.99M | Buy |
41,506
+5,536
| +15% | +$640K | 0.01% | 790 |
|
|
2020
Q2 | $4.37M | Buy |
35,970
+3,991
| +12% | +$441K | 0.01% | 728 |
|
|
2020
Q1 | $2.79M | Sell |
31,979
-1,635
| -5% | -$160K | 0.01% | 816 |
|
|
2019
Q4 | $3.59M | Buy |
+33,614
| New | +$3.52M | 0.01% | 834 |
|
|
2019
Q3 | – | Sell |
-11,279
| Closed | -$951K | – | 1843 |
|
|
2019
Q2 | $951K | Sell |
11,279
-1,085
| -9% | -$89.1K | ﹤0.01% | 1567 |
|
|
2019
Q1 | $1.09M | Buy |
12,364
+1,465
| +13% | +$122K | ﹤0.01% | 1355 |
|
|
2018
Q4 | $751K | Buy |
10,899
+641
| +6% | +$61.4K | ﹤0.01% | 1519 |
|
|
2018
Q3 | $1.26M | Hold |
10,258
| – | – | ﹤0.01% | 1424 |
|
|
2018
Q2 | $1.01M | Hold |
10,258
| – | – | ﹤0.01% | 1527 |
|
|
2018
Q1 | $852K | Hold |
10,258
| – | – | ﹤0.01% | 1563 |
|
|
2017
Q4 | $794K | Hold |
10,258
| – | – | ﹤0.01% | 1604 |
|
|
2017
Q3 | $608K | Hold |
10,258
| – | – | ﹤0.01% | 1669 |
|
|
2017
Q2 | $471K | Hold |
10,258
| – | – | ﹤0.01% | 1728 |
|
|
2017
Q1 | $443K | Hold |
10,258
| – | – | ﹤0.01% | 1736 |
|
|
2016
Q4 | $399K | Hold |
10,258
| – | – | ﹤0.01% | 1732 |
|
|
2016
Q3 | $519K | Hold |
10,258
| – | – | ﹤0.01% | 1652 |
|
|
2016
Q2 | $465K | Buy |
10,258
+1,796
| +21% | +$82.7K | ﹤0.01% | 1673 |
|
|
2016
Q1 | $334K | Hold |
8,462
| – | – | ﹤0.01% | 1047 |
|
|
2015
Q4 | $478K | Buy |
8,462
+1,527
| +22% | +$77.6K | ﹤0.01% | 918 |
|
|
2015
Q3 | $277K | Sell |
6,935
-150
| -2% | -$7.25K | ﹤0.01% | 1077 |
|
|
2015
Q2 | $337K | Hold |
7,085
| – | – | ﹤0.01% | 1118 |
|
|
2015
Q1 | $281K | Buy |
7,085
+2,450
| +53% | +$87.6K | ﹤0.01% | 1172 |
|
|
2014
Q4 | $103K | Hold |
4,635
| – | – | ﹤0.01% | 1725 |
|
|
2014
Q3 | $73K | Hold |
4,635
| – | – | ﹤0.01% | 1886 |
|
|
2014
Q2 | $69K | Hold |
4,635
| – | – | ﹤0.01% | 1781 |
|
|
2014
Q1 | $74K | Hold |
4,635
| – | – | ﹤0.01% | 1564 |
|
|
2013
Q4 | $44K | Buy |
+4,635
| New | +$45.2K | ﹤0.01% | 1866 |
|
Other funds holding NBIX
VPM
VCM
Canada Life's NBIX Position: Q1 2026 in Review
Canada Life increased its Neurocrine Biosciences (NBIX) stake by 0.77% in Q1 2026, buying an estimated $74K and bringing the position to 72,581 shares worth $9.57M. The position accounts for 0.02% of the portfolio, ranked #529.
Canada Life first reported a position in NBIX in Q4 2013 and has held it in 49 quarters since. The position peaked at $12.8M in Q4 2024. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Canada Life held 72,581 shares of Neurocrine Biosciences worth $9.57M as of Q1 2026.
- Canada Life bought 558 Neurocrine Biosciences shares in Q1 2026, an estimated $74K.
- Neurocrine Biosciences made up 0.02% of Canada Life's portfolio in Q1 2026, its #529 holding.
- Canada Life first reported a position in Neurocrine Biosciences in Q4 2013 and has held it in 49 quarters since.
- Canada Life's Neurocrine Biosciences position peaked at $12.8M in Q4 2024.
- 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Canada Life's 13F filing for Q1 2026, filed 14 May 2026.